Key Takeaways
- Cenexi drag persists, but Q4 breakeven in sight: Consolidated EBITDA margin fell to 21% from 23% YoY, entirely due to losses at Cenexi; the base business held a strong 34% EBITDA margin. Management is striving for Cenexi to reach positive EBITDA by Q4 FY25.
- U.S. and base business steady, ROW temporarily soft: U.S. sales grew 3% YoY on new launches and base product uptick, while ROW declined because Saudi Enoxaparin tender offtake did not repeat. Both the new Enoxaparin contract and Saudi orders are expected to resume this quarter.
- Cenexi turnaround is now a multi-year rebuild: The Fontenay ampoule line starts commercial production in January 2025, but the full margin recovery to the old 10% EBITDA level is guided only for FY27, a year later than the FY26 EBITDA-neutral target.
- New biologics and GLP-1 CDMO bets are early but tangible: A binding term sheet with Dr. Reddy’s for a biologics CDMO and three signed GLP-1 customer contracts add long-term optionality, though revenue timelines and peak potential remain undisclosed.
- What to watch next quarter: Whether the Saudi and Enoxaparin shipments actually dispatch, the pace of Cenexi’s monthly revenue run-rate improvement, and any update on the definitive biologics agreement with Dr. Reddy’s.
Cenexi: The Turnaround Timeline
- The Q2 hit: Cenexi revenue fell 5% YoY, partly due to an extended summer shutdown to install a new ampoule line at Fontenay and perform annual maintenance. The shutdown also meant the site ran for two months instead of three, temporarily lowering reported overheads without changing the fixed cost structure.
- Gross margin pressure: Consolidated gross margin dropped to 59% from 62%, driven by product mix at Cenexi, particularly lower uptake on the Belgium side. The base business gross margin was stable at 56%.
- Three-site progress report: The new high-capacity ampoule line at Fontenay is installed and on track for commercial production in January 2025. Hérouville is progressing validation batches for a new inactivated vaccine and ophthalmic gel, with commercial production expected before year-end. Braine-l’Alleud suffered a temporary lyophilizer breakdown but is running at full capacity on remaining units, with a backup unit coming in H1 2025.
- The margin path: Management expects Cenexi to reach positive EBITDA in Q4 FY25, then be EBITDA-neutral or low single-digit in FY26. Only in FY27, when all capacity is on stream and pipeline projects are commercial, does it expect to return to the old 10% EBITDA level.
- Utilization is the unlock: Two Cenexi plants are already fully utilized; the other two have technology transfers in progress with commercialization expected about a year out, putting them operational by Q1 FY26. The capex cycle completes in the next one to two years.
- Acquisition rationale intact but delayed: Gland bought Cenexi for its European generics brand presence, CDMO contracts, and technologies like controlled substances that Gland lacked. Management always knew it would be EBITDA-dilutive initially, but the efficiency timeline “took longer than what we anticipated because of the issues that we have there.”
Srinivas Sadu: “But we always knew that it will be EBITDA negative for us in terms of dilutive to Gland. But we also looked at how we can make it more efficient in a duration of time. But it took longer than what we anticipated because of the issues that we have there.”
Base Business: Steady Margin, Mixed Topline
- U.S. growth drivers: U.S. sales grew 3% YoY, supported by new product launches (four in the quarter) and an uptick in existing products. Management expects low double-digit U.S. growth in H2, driven by a combination of new launches, steadiness in the base business, and a ROW pickup.
- ROW drag is temporary: ROW declined because the Saudi Enoxaparin tender offtake did not happen last quarter, as stocks from the previous tender were still in the channel. The new Enoxaparin contract has not yet been dispatched, and the Civica contract partner has been signed up. Outside Saudi, the ROW business is growing: APAC is up, a product launched in South Africa, and Mexico business started last quarter.
- Standalone margin dynamics: Gland standalone gross margin declined ~1% YoY due to product mix and a profit share element, but improved QoQ on mix. Other expenses (ex-R&D) fell YoY because the prior year included consulting costs for the Cenexi acquisition and strategic advisory, plus power and fuel costs in India came down.
- R&D spend rising: R&D expenses increased from ₹35.1 crore to ₹49.3 crore, reflecting the commitment to adding new products. Management clarified that partners do not contribute to Gland’s R&D spend; it is 100% Gland-funded.
- Working capital improved: The cash conversion cycle improved to 149 days from 196 days.
Srinivas Sadu: “One is, of course, the new launches which will happen every quarter. That's one. Second, as I mentioned, Enoxaparin, the new contract that was signed, has not been dispatched yet. That will happen this quarter. The Civica contract, which our partner signed up. And the Saudi business is not gone. So, that will start again from this quarter.”
New Bets: Biologics CDMO and GLP-1
- Dr. Reddy’s biologics collaboration: Gland entered a binding term sheet with Dr. Reddy’s to establish a strategic Biologics CDMO collaboration, leveraging the manufacturing facility at Genome Valley, Hyderabad. A definitive agreement is expected soon, with initial financial benefits from Q1 FY26. Management declined to disclose which markets the agreement covers or peak revenue potential.
- GLP-1 CDMO contracts signed: Three different customers have been signed for GLP-1 products on the CDMO side, targeting regulated markets. Supply start dates cannot be disclosed due to client product patents.
- Biologics CMO economics: When Dr. Reddy’s supply starts, costs may rise somewhat, but management expects the business to cover all its costs. Revenue milestones are “too early to comment” on.
- Strategic rationale: The Dr. Reddy’s contract provides experience and learning in biologics CDMO, and tangible discussions with other players are ongoing.
Product Pipeline and Capacity Expansion
- Filing and approval momentum: Gland filed seven ANDAs and received approval for eight ANDAs during the quarter. It launched six molecules across key markets, including four in the U.S.
- Complex products in the queue: Three more complex products are expected to be approved soon, though no specific timeline was given.
- Latanoprostene tentative approval: Received tentative approval for Latanoprostene eye drops in the U.S., but management declined to comment on launch timing due to a para-IV settlement.
- India capacity build-out: New capex at Pashamylaram, including a bag line, microsphere dry powder line, and hormones/suspensions line, is coming onstream from next year. Management expects this to bring asset turnover back to the old 2x–2.5x rate.
- Pipeline depth question: When asked why Gland does not file 2x–3x more products given the low cost per ANDA, management pointed to the limited pipeline (363 already filed), the shift toward complex products, and R&D capability constraints, without directly addressing the payback period.
Leadership and Strategic Direction
- CEO transition: Shyamakant Giri has been appointed as CEO. Srinivas Sadu moves to a strategic, long-term role with more focus on Cenexi, which “needs a bit more focus.”
- Frontend strategy under evaluation: Gland is actively evaluating the option of putting up a frontend in emerging markets, weighing pros and cons.
- China market adaptation: The company is adapting its development strategy to address evolving market dynamics in China, though no specifics were provided.
- Annual maintenance rhythm established: The annual maintenance shutdown will occur every August, lasting 3–4 weeks. In the first couple of years, Gland will use that window to install additional capacity.
Srinivas Sadu: “I think it's more to strengthen the senior leadership to grow the business, and I'll be taking the role of more strategic and long-term - mid to long-term initiatives and also a bit more time at probably Cenexi because it needs a bit more focus.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | Low double-digit growth expected | FY25 |
| U.S. top-line growth | Low double-digit growth | H2 FY25 |
| Cenexi positive EBITDA | Achieve positive EBITDA | Q4 FY25 |
| Cenexi EBITDA neutral / low single-digit | Driven by revenue above EUR 200 million threshold | FY26 |
| Cenexi 10% EBITDA margin | All capacity on stream, pipeline projects commercial | FY27 |
| Fontenay ampoule line commercial production | New high-capacity line operational | January 2025 |
| Hérouville commercial production | New inactivated vaccine and ophthalmic gel | Before end of FY25 |
| Braine-l’Alleud lyophilizer resolution | Issue fully resolved; backup unit installed | Current quarter / H1 2025 |
| Enoxaparin new contract dispatch | Shipment to occur | Current quarter (Q3 FY25) |
| Saudi business resumption | Order pickup expected | H2 FY25 |
| Biologics CDMO initial financial benefits | From Dr. Reddy’s collaboration | Q1 FY26 |
| India asset turnover recovery | New Pashamylaram lines onstream, return to 2x–2.5x | FY26 onwards |
| Cenexi plant utilization (two remaining plants) | Technology transfers complete, commercialization operational | Q1 FY26 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated revenue from operations | ₹1,405.8 cr, +2% YoY |
| Base business revenue growth | +5% YoY |
| H1 FY25 consolidated revenue | ₹2,807.5 cr, +9% YoY |
| Other income | ₹59.6 cr (₹54.2 cr interest on fixed deposits, ₹4.5 cr forex gains) |
| Consolidated gross margin | 59%, vs 62% in Q2 FY24 |
| Base business gross margin | 56%, stable |
| Consolidated EBITDA | ₹296.1 cr, 21% margin vs ₹320.5 cr and 23% margin in Q2 FY24 |
| Base business EBITDA margin | 34%, similar to prior year |
| Net profit | ₹163.5 cr, -16% YoY |
| R&D expenditure | ₹49.3 cr, 4.6% of base business revenue, up from ₹35.1 cr in Q2 FY24 |
| Effective tax rate | 26% |
| Capital expenditure | ₹103.7 cr, primarily for Pashamylaram modular expansion and Cenexi |
| Cash flow from operations (H1 FY25) | ₹643.6 cr |
| Net cash position | ₹2,541.3 cr (cash and equivalents ₹2,820.1 cr, after Cenexi debt) |
| Cash conversion cycle | 149 days, improved from 196 days in Q2 FY24 |
| U.S. sales growth | +3% YoY |
| U.S. volume growth | +13% YoY, +5% QoQ |
| New product contribution in U.S. (H1 FY25) | ~₹60 cr |
| Rest of World revenue share | 19% of total revenue, similar to Q2 FY24 |
| India market revenue | ₹87.4 cr, 6% of total revenue |
| Profit share | 8% of revenue excluding Cenexi |
| Milestone income | 7% of revenue excluding Cenexi |
| Cenexi revenue | ₹339.9 cr (€37 mn), -5% YoY |
| Cenexi gross contribution | 69% |
| Cenexi EBITDA | negative ₹68.5 cr (negative €7.5 mn) |
| Total U.S. ANDA filings | 363 filed, 304 approvals, 59 pending |
| Global product registrations | 1,726 |
| Complex products filed | 9 filings completed out of 19 targeted, 6 approved and launched |
| Complex products IQVIA market opportunity | $7.3 bn |
| China market approvals | 5 approvals out of 9 products in plan |
| Biologics CDMO capacity (Genome Valley) | 8,000 litres mammalian single-use DS capacity |
| Biologics CDMO site investment | ~₹300 cr |
| Biologics CDMO quarterly running cost | ₹3–4 cr per quarter |